Abstract:The major targets of current drugs used in mental health, such as neurotransmitter receptors and transporters, are based on serendipitous findings from several decades ago, and there is currently a severe drought of new drug targets. There is a pressing need for novel drugs, and much hope has been placed on the use of molecular genetics to help define them. However, despite evidence for a genetic basis to schizophrenia stretching back for over a century, and a heritability of about 80%, the identification of susceptibility genes has been an uphill struggle. Candidate gene studies, which have generally focussed on obvious candidates from the dopamine and serotonin systems, as well as genes involved in brain development, have not generally been successful, although meta-analysis indicates that the dopamine D3 receptor gene (DRD3) and the serotonin receptor gene type 2A (HTR2A) may have a very small influence on risk. Linkage analysis has provided robust evidence of genetic loci, for example, on chromosomes 8p, 13q and 22q, and also implies shared genetic aetiology with bipolar disorder. The identification of these loci together with advances in genetic technology, especially the characterisation of polymorphisms, the understanding of haplotypes and the development of statistical methods, has lead to the identification of several plausible susceptibility genes, including neuregulin 1, proline dehydrogenase and dysbindin. Interestingly, these genes point more towards a role for the glutamate pathway rather than the dopamine pathway in schizophrenia. We have attempted to replicate some of these findings in schizophrenic patients from SW China, and we find significant association with a novel neuregulin 1 haplotype, with proline dehydrogenase polymorphisms, but not with catechol-O-methyltransferase (COMT). The replication of neuregulin 1 association on chromosome 8p by several investigators is the most convincing to date, and the presence of a syndrome similar to dementia praecox of 8p linked families, and the lack of linkage of bipolar disorder to this region is a testament to the ideas of Kraepelin more than 100 years ago.

No association between schizophrenia and homozygosity at the D3 dopamine receptor gene.

No association between alleles or genotypes at the dopamine transporter gene and schizophrenia.

The Relationship Between Drd2 Gene Polymorphisms (c957t and C939t) and Schizophrenia: A Meta-Analysis

The genetics of schizophrenia: glutamate not dopamine?

No Genetic Association Between Dopamine D1 Receptor Gene and [early Onset] Schizophrenia

Association Study of Dopamine Receptor Genes Polymorphisms with the Risk of Schizophrenia in the Han Chinese Population

No Association of SLC6A3 and SLC6A4 Gene Polymorphisms with Schizophrenia in the Han Chinese Population.

An Association Study Between Dopamine D1 Receptor Gene Polymorphisms and the Risk of Schizophrenia.

No Association Between SLC6A2, SLC6A3, DRD2 Polymorphisms and Schizophrenia in the Han Chinese Population.

[Association Analysis Between Dopamine D1 Receptor Gene and Symptom Quantitative Trait of Schizophrenia].

Converging Evidence Implicates the Dopamine D3 Receptor Gene in Vulnerability to Schizophrenia

The Ser9gly Polymorphism of the Dopamine D3 Receptor Gene and Risk of Schizophrenia: an Association Study and A Large Meta-Analysis

Association Analysis of Polymorphisms in the Upstream Region of the Human Dopamine D4 Receptor Gene in Schizophrenia.

[Association of Schizophrenia with a Promoter Polymorphism in the Dopamine D2 Receptor Gene].

[Schizophrenia and Dopamine D4 Gene Polymorphism in Chinese Population: Association Analysis].

[Associations Between Six Functional Genes and Schizophrenia].

Association Between MBD3 Gene Polymorphism and Schizophrenia

Disequilibrium transmission of the Ser9Gly polymorpphism of the dopamine D3 receptor gene in 151 Chinese pedigrees

Association Between A-241G Polymorphism of Dopamine D_2 Receptor Promoter Gene and Schizophrenia in Chinese

Associations Between Dopamine D2 Receptor Gene Polymorphisms and Schizophrenia Risk: a PRISMA Compliant Meta-Analysis.

[Study on the Genetic Association Between DRB3 and DRB1 Loci in the Human MHC Region and Psychotic Symptoms of Schizophrenia].